TEL: (212)616-4899

Athira Pharma, Inc. Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Athira Pharma, Inc. (NASDAQ: ATHA) who purchased between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company’s registration statement issued in connection with the Company’s September 2020 initial public offering priced at $17.00 per share. The action, which was filed in the United States District Court for the Western District of Washington, alleges that the Company violated federal securities laws.

In particular, the Athira Pharma lawsuit alleges that (1) the research conducted by Defendant Kawas, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.

Shareholders have until August 24, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

Keep Me Informed

There is no cost or obligation. This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

Privacy Policy